Predict your next investment

Government
nih.gov

See what CB Insights has to offer

Investments

661

Funds

3

Partners & Customers

10

About National Institutes of Health

The National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services, is the nation's medical research agency making important medical discoveries that improve health and save lives.

National Institutes of Health Headquarter Location

9000 Rockville Pike

Bethesda, Maryland, 20892,

United States

301-496-4000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing National Institutes of Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find National Institutes of Health in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

M

Medical Devices

66 items

https://mdic.org/membership/our-members/

Latest National Institutes of Health News

Rensselaer Researchers Receive $3.5 Million Grant for Development of COVID Antiviral Drug

Jun 28, 2022

Rensselaer Polytechnic Institute researchers will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a low-dose, oral COVID antiviral drug that can be administered at home. “Our role in the project is to develop novel inhibitors of the two key proteases of the SARS-CoV-2 virus, called CLpro and PLpro, which are essential to the virus life cycle,” says researcher  Gaetano Montelione , the Constellation Endowed Chair of Structural Bioinformatics. The team’s work will build upon Montelione’s previous research on COVID antiviral drug options. First, using bioinformatics, Montelione and his team found that a key protein from the hepatitis C virus closely resembles the coronavirus CLpro protease structure. Since several Food and Drug Administration (FDA)-approved drugs target the hepatitis C protease, the next step was to determine if any of those drugs would also bind and block proteases of SARS-CoV-2. In research published in Cell Reports,  the team found that, out of the 10 hepatitis C drugs tested, seven suppressed the SARS-CoV-2 virus. Three of those drugs were acting not only on the main protease, CLpro, but on the PLpro protease, as well. Next, they discovered that, when combined with the polymerase inhibitor remdesivir, these drugs multiplied remdesivir’s antiviral activity by as much as tenfold. Those that only inhibit CLpro did not amplify remdesivir’s effect. “Inhibiting PLpro seems to be important,” says Christopher Cioffi , Thomas and Constance D’Ambra Endowed Chair of Organic Chemistry. “This induces synergy with other antivirals such as remdesivir, which is currently being used to treat people with COVID-19. Now, we will work toward making new and orally bioavailable PLpro inhibitors based on Montelione’s biophysical analysis. We will look at the structure of the protein’s active site and design molecules that fit into it and bind with optimal affinity.” CLpro will also be targeted. “One of the big challenges is that the target will evolve to escape the drug,” Montelione says. “This is particularly problematic with rapidly mutating viruses like COVID-19. To overcome that, we try to hit multiple targets. By hitting both CLpro and PLpro simultaneously, there is less likelihood of antiviral resistance.” It is hoped that the most promising COVID antiviral drug to come out of the AViDD centers will enter late-stage preclinical development. Industry partners will provide valuable resources to accelerate their movement through the product development pipeline. Drugs that are already FDA-approved for treating different diseases may be approved quicker for the treatment of COVID-19, as well. Share:

National Institutes of Health Investments

661 Investments

National Institutes of Health has made 661 investments. Their latest investment was in Reliant Glycosciences as part of their Grant on June 6, 2022.

CBI Logo

National Institutes of Health Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/15/2022

Grant

Reliant Glycosciences

$1.2M

Yes

1

6/9/2022

Grant

Bright Uro

$2M

Yes

2

6/9/2022

Grant - IV

Phase Genomics

$5.5M

Yes

1

6/7/2022

Grant - II

Subscribe to see more

$99M

Subscribe to see more

10

5/24/2022

Grant

Subscribe to see more

Subscribe to see more

10

Date

6/15/2022

6/9/2022

6/9/2022

6/7/2022

5/24/2022

Round

Grant

Grant

Grant - IV

Grant - II

Grant

Company

Reliant Glycosciences

Bright Uro

Phase Genomics

Subscribe to see more

Subscribe to see more

Amount

$1.2M

$2M

$5.5M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

National Institutes of Health Fund History

3 Fund Histories

National Institutes of Health has 3 funds, including West Nile Grant.

Closing Date

Fund

Fund Type

Status

Amount

Sources

West Nile Grant

1

Dengue Grants - UC1

10

Dengue Grants - UO1

10

Closing Date

Fund

West Nile Grant

Dengue Grants - UC1

Dengue Grants - UO1

Fund Type

Status

Amount

Sources

1

10

10

National Institutes of Health Partners & Customers

10 Partners and customers

National Institutes of Health has 10 strategic partners and customers. National Institutes of Health recently partnered with IliAD Biotechnologies on April 4, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

4/26/2022

Vendor

United States

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform

ILiAD Biotechnologies , LLC collaborators for the National Institutes of Health grant include co-principal investigator Dr. Camille Locht , Inserm U1019 located at Institut Pasteur de Lille , ILiAD Biotechnologies , LLC 's wholly owned subsidiary , BioLyo Technologies , and The Commissariat à l'énergie atomique et aux energies alternatives department of Infectious disease models for innovative therapies .

2

2/7/2022

Vendor

United States

Qorvo Biotechnologies Awarded $4.1 Million National Institutes of Health Contract for SARS-CoV-2/ Flu Combo and Antigen Pooling - Qorvo

Combined with a previous National Institutes of Health contract award of $ 24.4 million , this award positions Qorvo , Inc. to accelerate the production and market launch of multiple COVID testing solutions using a single platform .

2

1/19/2022

Vendor

United States

1

1/11/2022

Licensee

United States

Subscribe to see more

Subscribe to see more

10

1/3/2022

Licensee

United States

Subscribe to see more

Subscribe to see more

10

Date

4/26/2022

2/7/2022

1/19/2022

1/11/2022

1/3/2022

Type

Vendor

Vendor

Vendor

Licensee

Licensee

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform

ILiAD Biotechnologies , LLC collaborators for the National Institutes of Health grant include co-principal investigator Dr. Camille Locht , Inserm U1019 located at Institut Pasteur de Lille , ILiAD Biotechnologies , LLC 's wholly owned subsidiary , BioLyo Technologies , and The Commissariat à l'énergie atomique et aux energies alternatives department of Infectious disease models for innovative therapies .

Qorvo Biotechnologies Awarded $4.1 Million National Institutes of Health Contract for SARS-CoV-2/ Flu Combo and Antigen Pooling - Qorvo

Combined with a previous National Institutes of Health contract award of $ 24.4 million , this award positions Qorvo , Inc. to accelerate the production and market launch of multiple COVID testing solutions using a single platform .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.